Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 8, 2007. The report details a specific corporate action regarding the repurchase of the company's own shares in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 3,250,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,196.56 pence per share.
- Treasury Holdings: Following the purchase, the Company holds 483,379,158 shares in Treasury.
- Treasury Percentage: Treasury shares represent 8.72% of total voting rights.
- Shares in Issue: 5,541,850,509 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares due to the repurchase of 3,250,000 shares on November 8, 2007. This transaction increased the Company's Treasury shareholding to 8.72% of total voting rights. The filing text does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on future performance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying 3,250,000 shares by the price of 1,196.56 pence.
- Confirm the updated total voting rights denominator (5,541,850,509 shares) for compliance with disclosure thresholds.
- Review the Company's Annual Report (Form 20-F) for full financial performance data, as this filing is limited to the share buyback announcement.